[Federal Register Volume 78, Number 228 (Tuesday, November 26, 2013)]
[Notices]
[Pages 70531-70532]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-28353]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign Trade Zones Board

[B-98-2013]


Foreign-Trade Zone (FTZ) 93--Raleigh/Durham, North Carolina; 
Notification of Proposed Production Activity; GlaxoSmithKline, PLC 
(Pharmaceutical Products); Zebulon, North Carolina

    The Triangle J Council of Governments, grantee of FTZ 93, submitted 
a notification of proposed production activity to the FTZ Board on 
behalf of GlaxoSmithKline, PLC (GlaxoSmithKline), located in Zebulon, 
North Carolina. The notification conforming to the requirements of the 
regulations of the FTZ Board (15 CFR 400.22) was received on November 
18, 2013.
    The GlaxoSmithKline facility is located within Site 6 of FTZ 93. 
The facility is used for the production and packaging of pharmaceutical 
products. Pursuant to 15 CFR 400.14(b), FTZ activity would be limited 
to the specific foreign-status materials and components and specific 
finished products listed in the submitted notification (as described 
below) and subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt GlaxoSmithKline from

[[Page 70532]]

customs duty payments on the foreign status components used in export 
production. On its domestic sales, GlaxoSmithKline would be able to 
choose the duty rates during customs entry procedures that apply to 
inhalers, tablets, and capsules which treat a variety of medical 
conditions (duty rates range from free to 6.4%) for the foreign status 
inputs noted below. Customs duties also could possibly be deferred or 
reduced on foreign status production equipment.
    The finished products include devices such as respiratory placebo 
inhalers, Relenza anti-viral inhalers, Seretide/Advair, Serevent and 
Flovent diskus respiratory inhalers, Advair and Ventolin HFA 
respiratory inhalers, and the following tablets and capules--Lovaza 
antihyperlipidemic, Paxil depression, Avandamet metabolic, Avandary 
metabolic, Avandia metabolic, Lamictal central nervous system (CNS), 
Potiga CNS, Amerge CNS, Horizant CNS, Imitrex CNS, Lamictal ODT CNS, 
Requip/Requip XL CNS, Treximet CNS, Telzir anti-viral, Valtrex anti-
viral, Zovirax anti-viral, Wellbutrin/Buproprion depression, Zantac 
gastrointestinal (GI), Zofran GI, Votrient urology, Coreg CR 
cardiovascular, Rythmol cardiovascular, Innopran XL hypertension, Jalyn 
urology, Avodart urology, Lanoxin cardiovascular, Malarone anti-
malarial, Promacta immune thrombocytopenia (ITP), and Tykerb oncology.
    The components and materials sourced from abroad include corn 
starch, carnuba wax, lactose monohydrate, fluticasone/salmeterol 
placebo diskus (a type of inhaler), respiratory placebo inhaler, silica 
colloidal anhydrous, precipitated calcium carbonate, pharmaceutical 
talc, zephex 134a propellant, mannitol, magnesium stearate, stearic 
acid, potassium sorbate, propafenon hcl, bupropion hydrochloride, 
melphalan, albuterol sufate, salbuterol sulfate, salmeterol, vilanterol 
trifenatate, umeclidinium api, paracetamol, ezogabine (retigabine), 
paracetamol, metformin hydrochloride, ranitidine hydrochloride, 
zanamivir, ondansetron hydrochloride, abacavir sulfate, valacyclovir 
hydrochloride, lamotrigine, rosiglitazone maleate, paroxetine 
hydrochloride, lamivudine, zidovudine, pazopanib, fluticasone 
propionate, fluticasone furoate, dutasteride, Lovaza capsules, breo 
ellipta inhalers, avodart capsules, flovent diskus, Paxil tablets, 
lexiva oral suspension, sumatriptan succinate/naproxen (Treximet), 
abacavir/lamivudine tablets (epzicom) tablets, atovaquone and proguanil 
hcl tablets, combivir tablets, dolutegravir tablets, epivir tablets, 
epzicom tablets, malarone tablets, ziagen tablets, Zantac tablets, 
mekinist tablets, trametinib tablets, pazopanib tablets, tafinlar 
capsules, votrient tablets, coreg cr capsules, flolan for injection, 
propafenon sr, Rythmol (proafenon) sr, Amerge tablets, imigran 
injection, imitrex bulk pack, sumatriptan succinate 85mg/naproxen, 
lamictal, parnate tablets, ondansetron odt bulk, requip tablets, 
soriatane (acitretin) capsules, Zofran, Ventolin actuator dose counter, 
Advair diskus, Advair diskus inhalation powder, fluticasone/salmeterol 
aerosol inhalers, Ventolin samples, Seretide, argatroban, arixtra, 
Avandamet tablets, Avandia tablets, dutasteride-tamsulosin hcl fdc 
capsules, eltrombopag, flolan sterile diluent, Jalyn fixed dose 
combination capsules, panadol tablets, opadry (an excipient), starch 
pregel, Avandamet placebo tablets, placebo diskus, nasal spray demo 
pack, respiratory placebo, triacetin, crospovidone, povidone, 
spectracel, alginic acid ep, 20 micron aluminum powder, empty aerosol 
cans, pressure can spray valves, diskus subassemblies, multi-dose 
powder inhalers, novel dry powder inhalers, multi-dose powder inhaler 
subassembly and placebo, multi-dose powder inhaler diskus devices, 
actuators--and their dose counters and assemblies (duty rates range 
from free to 6.5%).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the FTZ Board's Executive Secretary at the 
address below. The closing period for their receipt is January 6, 2014.
    A copy of the notification will be available for public inspection 
at the Office of the Executive Secretary, Foreign-Trade Zones Board, 
Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW., 
Washington, DC 20230-0002, and in the ``Reading Room'' section of the 
FTZ Board's Web site, which is accessible via www.trade.gov/ftz.
    For further information, contact 
Diane.Finver[com x mat]trade.gov or (202) 482-1367.

    Dated: November 19, 2013.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2013-28353 Filed 11-25-13; 8:45 am]
BILLING CODE 3510-DS-P